Statin use correlates with reduced glaucoma risk and disease progression

An analysis comparing over 420,000 individuals found that statin users had a 15% lower risk of developing open-angle glaucoma compared to non-users. Among people already diagnosed with glaucoma, those taking statins showed significantly reduced need for surgical intervention, with a 36% lower risk of requiring glaucoma surgery. While statins are primarily used to lower cholesterol, the findings suggest they may also provide protective effects against optic nerve damage through mechanisms that remain poorly understood.

Glaucoma ranks among the leading preventable causes of blindness worldwide, characterized by irreversible damage to the optic nerve that often progresses silently. The research team accessed an unusually large patient database spanning 165 million individuals, enabling direct comparison between statin users and non-users across extended follow-up periods. The disparities in surgical intervention rates were particularly striking, with statin users requiring conventional eye surgery at roughly one-third the rate of those not on the medication.

The mechanisms underlying statins' apparent protective effects remain unclear, though prior research suggests these cholesterol-lowering drugs may inhibit nerve cell deterioration through pathways distinct from their primary cardiovascular function. Researchers explicitly note the study's observational design limits causal inference, and they acknowledge missing clinical details—such as precise pressure measurements within the eye—that would clarify whether reduced surgery rates reflect slower disease progression or simply deferred intervention.